LONDON, Feb. 18, 2020 /PRNewswire/ -- ReNeuron Group plc
(AIM: RENE), a global leader in the development of cell-based
therapeutics, is pleased to announce the publication in a peer
reviewed journal of positive clinical data from the PISCES II Phase
2a clinical trial of its CTX stem cell therapy candidate for
disability resulting from stroke. The article, titled
"Intracerebral implantation of human neural stem cells and motor
recovery after stroke: multicentre prospective single-arm study
(PISCES-2)," was published online in the Journal of Neurology,
Neurosurgery, and Psychiatry. Data from the study were originally
presented by Professor Keith Muir at
the American Heart Association International Stroke Conference 2018
(ISC 2018) in January 2018, having
been announced by the Company in October
2017.
"We are delighted to see the positive results of the PISCES II
clinical trial of our CTX cell therapy candidate for stroke
disability published in this highly regarded peer-reviewed
journal," commented Olav Hellebø, Chief Executive Officer of
ReNeuron.
PISCES II was a single arm, open-label study in patients living
with significant disability resulting from ischaemic stroke.
A total of 23 stable stroke patients with moderate to severe
disability were treated with a single dose of 20 million CTX cells
a median of seven months post-stroke. Clinically meaningful
improvements in disability scales were measured out to 12 months
post-implantation.
The greatest improvements on the Modified Rankin Scale
(mRS), a measure of disability and dependence, were seen in a
pre-specified group of fourteen subjects with residual movement of
the affected arm (NIHSS Upper Limb <4). Of these patients,
38.5% were responders (at least a one-point improvement on mRS) at
six months post treatment and 50% were responders at twelve months
post treatment on this measure. A one-point improvement in
mRS is proven to be clinically meaningful for patients, both in
terms of quality of life and healthcare resources needed to care
for them. For example, improving from mRS 3 to 2 means that a
person with a stroke regains their ability to live independently;
perhaps returning home from a care facility, or enabling a spouse
or carer to return to work.
The ongoing PISCES III study is a larger, randomised, placebo
controlled clinical trial designed to show a significant difference
in the proportion of patients with at least a one-point improvement
on mRS in a group receiving CTX stem cells compared to a group
receiving a sham-surgery procedure.
The full publication can be accessed here.
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead clinical-stage candidates are in
development for the blindness-causing disease, retinitis
pigmentosa, and for disability as a result of stroke.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that would
otherwise be unable to reach their site of action. ReNeuron's
shares are traded on the London AIM market under the symbol RENE.L.
For further information visit
www.reneuron.com.
Contacts:
|
|
|
|
ReNeuron
|
+44 (0) 20 3819
8400
|
Olav Hellebø, Chief
Executive Officer
|
Michael Hunt, Chief
Financial Officer
|
|
Buchanan (UK
Media/Investor Relations)
|
+44 (0) 20 7466
5000
|
Mark Court, Tilly
Abraham
|
|
Argot Partners
(US Media/Investor Relations)
|
+1 212 600
1902
|
Claudia Styslinger,
David Rosen
|
|
|
|
Stifel Nicolaus
Europe Limited (NOMAD and Joint Broker)
|
+44 (0) 20 7710
7600
|
Jonathan Senior,
Stewart Wallace, Ben Maddison
|
|
|
|
N+1 Singer
(Joint Broker)
|
+44 (0) 20 7496
3000
|
Aubrey Powell, James
Moat, Tom Salvesen
|
|
View original
content:http://www.prnewswire.com/news-releases/reneuron-announces-publication-of-positive-phase-2a-stroke-clinical-data-301006892.html
SOURCE ReNeuron Group plc